METHODS: In the present study, the dried roots of Hemidesmusindicus were crushed to a coarse powder and extracted with water under reflux for 36 hours to obtain the aqueous extract of roots of Hemidesmusindicus (AERHI). The extract was reconstituted in 2% aqueous tragacanth just before use and administered orally at a dose 0f 100 mg/kg, 300 mg/kg and 500 mg/kg. In a single dose study, the parameters were assessed after oral administration of the single dose of the AERHI, whereas in a multiple dose study, the animals daily received the suitable oral dose of the AERHI for a period of 30 days. The parameters were assessed on the 15th and 30th day. The antipsychotic activity was screened using Apomorphine induced Stereotyped behavior in rats and Haloperidol induced catalepsy models were used. In Apomorphine induced Stereotyped behavior inhibition of the Stereotyped behavior was considered to be anti-psychotic activity and in Haloperidol induced catalepsy, we observed whether the AERHI potentate or attenuate the catalepsy in rats.
RESULTS: In this study, the extract of Hemidesmusindicus significantly inhibited the stereotyped behavior induced by apomorphine in rats and also potentiate the catalepsy induced by haloperidol, thereby showing its anti-psychotic activity.
CONCLUSION: All these observations imply that Hemidesmusindicus extract possesses anti-psychotic activity in experimental animals.
METHODS: This evaluation was carried out as a randomized, placebo-controlled clinical study for 60 days at a daily dose of 300 mg. This study involved a total of 60 subjects randomized in the ratio of 1:1 to test group and placebo group. Multiple skin health parameters were evaluated before and after the intervention.
RESULTS: Data from this study indicated that Punica granatum extract significantly reduced crow's feet wrinkles, tactile roughness, forehead fine lines, forehead wrinkles and improved skin radiance compared to the placebo in 60 days. Other skin health attributes like pores, spots and UV pigmentation were also observed to exhibit significant changes. The test group showed a significant improvement in skin tone evenness, skin moisturisation, elasticity and firmness compared to the baseline. The Tyrosinase biomarker levels were observed to drop by 3% in the Grantria® supplemented group.
CONCLUSIONS: Grantria® was found to be effective, safe, and well accepted by the subjects making it a potential candidate for use in the supplements intended for maintaining healthy and glowing skin.
AREAS COVERED: The review provides a brief overview of the use of LCN in the treatment of NSCLC. It explores their composition, fabrication methods, and characterization processes. The article further addresses several nanoparticle-based approaches for the treatment of NSCLC. Ultimately, it underscores the promise of LCNs as a promising drug delivery system for NSCLC and discusses the obstacles and outlook in this field.
EXPERT OPINION: LCN represents a promising frontier in the treatment of NSCLC, offering several specific advantages over conventional therapies. Utilizing their intrinsic self-assembly characteristics, LCN provides meticulous control over drug encapsulation, release kinetics, and cellular absorption, which are crucial for improving therapy success. LCN also has the capability for co-delivery of various drugs, facilitating synergistic therapeutic benefits and addressing multidrug resistance, a prevalent issue in NSCLC treatment.